SESSION ONE: OVERVIEW OF THE GRAM NEGATIVE INFECTIONS LANDSCAPE

This session is of the following presentations:

What’s left in the cupboard? Older antimicrobials for treating gonorrhoea
Dr Helen Fifer, Consultant microbiologist, UK Health Security Agency (UKHSA)

Recent updates from EUCAST: the impact of guidance on MDT practices
Dr Nick Brown, Consultant Medical Microbiologist, Cambridge University Hospitals NHS Trust

Exotic and imported infections: Burkholderia pseudomallei
Professor David Dance, Honorary Visiting Research Fellow/Honorary Professor, Lao-Oxford-Mahosot Hospital- Wellcome Trust Research Unit/University of Oxford/ London
School of Hygiene and Tropical Medicine

NICE funding models – what do we want next for delinkage?
Miss Beth Woods, Senior Research Fellow, University of York

Q&A

SESSION THREE: A ONE HEALTH VIEW ON ANTIMICROBIAL RESISTANCE

This session is of the following presentations:

Veterinary approaches to antimicrobial use and stewardship
Professor Roberto La Ragione, Head of the Department of Pathology and Infectious Diseases and Deputy Head of the School of Veterinary Medicine, University of Surrey

Antimicrobials in the environment – how much is too much?
Dr Aimee Murray, Lecturer, University of Exeter

Protecting the environment through legislation
Natalie Louise Bennett, Baroness Bennett of Manor Castle

Q&A

SESSION FIVE: WHAT LESSON HAVE WE LEARNT ON AMR?

This session is of the following presentations:

What has been the impact of COVID-19 on Gram-negative resistance?
Dr Sarah Gerver, Head of the Antimicrobial Resistance and Prescribing Section at the UK Health Security Agency

Optimising antimicrobial prescribing
Mrs Frances Garraghan, Lead Antimicrobial Pharmacist, Manchester University NHS Foundation Trust

Debate – stewardship in the era of COVID-19
Mrs Frances Garraghan, Lead Antimicrobial Pharmacist, Manchester University NHS Foundation Trust & Dr Alicia Demirjian, Consultant, Paediatric Infectious Diseases; Epidemiologist Evelina London Children’s Hospital; UK Health Security Agency (UKHSA)

Q&A